One concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.
Following on from Dr.RenalNash — and this may be the naive question:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
FDA_TrackerJim said:For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.
I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemFDA_TrackerJim said:For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.
Agreed, and the adaptation point cuts both ways: tachyphylaxis to gastric emptying is why tolerability improves, and it is also why people who were relying on physical fullness feel the effect fade while the appetite effect is still working.
FDA_TrackerJim said:For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.
That reframing is the part I needed. Adding it to my notes with a link back to this thread.